NCT01650194已完成2 期
A Phase 2 Study Determining Safety and Tolerability of Enzalutamide (Formerly MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Number of Participants With Adverse Events (AEs)
研究概览
简要总结
The purpose of this study was to explore the safety and tolerability of enzalutamide in combination with abiraterone acetate plus prednisone. Subjects diagnosed with cancer of the prostate that was getting worse and spreading to the bone despite receiving hormone treatment were enrolled and received study treatment until disease progression.
详细描述
For the study duration, all subjects maintained androgen deprivation with a gonadotropin releasing hormone (GnRH) agonist or antagonist or orchiectomy. Study drug was administered until disease progression. Disease progression was defined as a composite endpoint consisting of either clinical deterioration, radiographic progression or prostate-specific antigen (PSA) progression according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
- •Presence of metastatic disease to the bone
- •Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., surgical or medical castration)
- •Subject receiving bisphosphonate or denosumab therapy must have been on stable doses for at least 4 weeks prior to Day 1
- •Progressive disease defined as one or more of the following three criteria (Note: subjects who received an antiandrogen must demonstrate disease progression following discontinuation of antiandrogen):
- •PSA progression defined by a minimum of two rising PSA levels with an interval of ≥ 1 week between each determination. The PSA value at the Screening visit should be ≥ 2 ng/mL
- •Soft tissue disease progression as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
- •Bone disease progression defined by PCWG2 criteria (two or more new lesions on bone scan compared with prior scan)
- •Subject previously treated with chemotherapy must have no more than two prior chemotherapy regimens for the treatment of metastatic prostate cancer
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- •Agree to use a double-barrier method of contraception which involves the use of a condom in combination with one of the following: contraceptive sponge, diaphragm, or cervical ring with spermicidal gel or foam, if having sex with a woman of child-bearing potential during the length of the study and for one week after abiraterone is discontinued and for at least three months after enzalutamide is discontinued
- •Subject agrees not to participate in another interventional study while on treatment
排除标准
- •Known or suspected metastases in the brain
- •Absolute neutrophil count < 1,000/μL, platelet count < 75,000/μL, and hemoglobin < 9 g/dL (NOTE: subject may not have received any growth factors or blood transfusions within seven days of the hematologic laboratory values obtained at the Screening visit)
- •Total bilirubin (TBL), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal
- •Creatinine (Cr) > 2 mg/dL
- •Treatment with androgen receptor antagonists (bicalutamide, flutamide, nilutamide), 5-α reductase inhibitors (finasteride, dutasteride), estrogens, chemotherapy, or biologic therapy within 4 weeks of Day 1 visit
- •Radiation therapy within 3 weeks (if single fraction of radiotherapy within 2 weeks) of Day 1 visit, or radionuclide therapy within 8 weeks of Day 1
- •Planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery
- •Structurally unstable bone lesions suggesting impending fracture
- •History of seizure or any condition that may predispose to seizure including, but not limited to underlying brain injury, stroke, primary brain tumors, brain metastases, or alcoholism. Also, history of loss of consciousness or transient ischemic attack within 12 months of enrollment (Day 1 visit)
- •Clinically significant cardiovascular disease including:
- •Myocardial infarction within 6 months of Screening visit;
- •Uncontrolled angina within 3 months of Screening visit;
- •Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless a screening echocardiogram or multi-gated acquisition scan (MUGA) performed within three months of the Screening visit results in a left ventricular ejection fraction that is ≥ 45%
- •History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsade de pointes)
- •Prolonged corrected QT interval by the Fridericia correction formula (QTcF) on the Electrocardiogram (ECG) > 470 msec.
- •History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place
- •Hypotension (systolic blood pressure < 86 mmHg or bradycardia with a heart rate of <50 beats per minute on the ECG., unless pharmaceutically induced and thus reversible (i.e. beta blockers).
- •Uncontrolled hypertension as indicated by a resting systolic blood pressure >170 mmHg or diastolic blood pressure >105 mmHg
- •Prior use of ketoconazole, abiraterone acetate or enzalutamide, or participation in a previous clinical trial of ketoconazole, abiraterone acetate or enzalutamide
- •History of significant bleeding disorder unrelated to cancer, including:
- •Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
- •Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) of Screening visit
- •History of GI bleeding within 6 months of Screening visit
- •Active or symptomatic viral hepatitis or chronic liver disease
- •Known history of pituitary or adrenal dysfunction
研究组 & 干预措施
Enzalutamide + Abiraterone + Prednisone
Experimental
Participants received enzalutamide combined with abiraterone acetate once daily plus prednisone twice daily.
干预措施: enzalutamide (Drug)
Enzalutamide + Abiraterone + Prednisone
Experimental
Participants received enzalutamide combined with abiraterone acetate once daily plus prednisone twice daily.
干预措施: abiraterone acetate (Drug)
Enzalutamide + Abiraterone + Prednisone
Experimental
Participants received enzalutamide combined with abiraterone acetate once daily plus prednisone twice daily.
干预措施: prednisone (Drug)
结局指标
主要结局
Number of Participants With Adverse Events (AEs)
时间窗: From the first dose of study drug administration up 30 days following the last dose of study drug date, with a median duration of treatment of 10.1 months.
A treatment-emergent adverse event (TEAE) was defined as an adverse event occurring or worsening between the start of study treatment date and the latest date of 30 days after the last dose date or the 30-day follow-up visit date, and not later than the data cut-off date or the date of death. AEs, including abnormal clinical laboratory values, were graded using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) guidelines (V4.03).
次要结局
- Change From Baseline in Testosterone Concentration in Bone Marrow Aspirate(Baseline and Week 9)
- Change From Baseline in Dihydrotestosterone (DHT) Concentration in Bone Marrow Aspirate(Baseline and Week 9)
- Change From Baseline in Cortisol in Bone Marrow Aspirate(Baseline and Week 9)
- Change From Baseline in Androstenedione in Bone Marrow Aspirate(Baseline and Week 9)
- Change From Baseline in Progesterone in Bone Marrow Aspirate(Baseline and Week 9)
- Change From Baseline in Pregnenolone in Bone Marrow Aspirate(Baseline and Week 9)
- Change From Baseline in Androstenedione Concentration in Blood(Baseline and Week 9)
- Change From Baseline in Pregnenolone Concentration in Blood(Baseline and Week 9)
- Change From Baseline in Testosterone Concentration in Blood(Baseline and Week 9)
- Change From Baseline in DHT Concentration in Blood(Baseline and Week 9)
- Change From Baseline in Cortisol Concentration in Blood(Baseline and Week 9)
- Change From Baseline in Progesterone Concentration in Blood(Baseline and Week 9)
- Change From Baseline to End-of-Treatment (EoT) in Prostate-Specific Antigen (PSA) Levels(Baseline and EoT; the median duration of treatment was 10.1 months.)
- Progression Free Survival (PFS)(Up to 1849 days)
- Percentage of Participants With Objective Response for Soft Tissue Lesions According to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST)(Up to 1849 days)
- Bone Scan Response at EoT(EoT; the median duration of treatment was 10.1 months.)
- Change From Baseline to EoT in Bone Specific Alkaline Phosphatase(Baseline and EoT; the median duration of treatment was 10.1 months.)
- Change From Baseline in Urine N-Telopeptide(Baseline and Week 9)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder CancerCarcinoma, Transitional CellRenal Pelvis CancerUreter CancerUrethra CancerBladder CancerNCT02300610H. Lee Moffitt Cancer Center and Research Institute10
已完成
4 期
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate CancerProstate CancerNCT02918968Astellas Pharma Inc206
已完成
2 期
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior TherapiesAdvanced Epithelial OvarianRecurrent Epithelial OvarianFallopian TubePrimary Peritoneal CarcinomaNCT01974765Memorial Sloan Kettering Cancer Center59
进行中（未招募）
2 期
Enzalutamide for Patients With Androgen Receptor Positive Salivary CancersSalivary CancerNCT02749903Alliance for Clinical Trials in Oncology46
已完成
2 期
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic TumoursNeuroendocrine TumorsPancreatic NeoplasmsNCT02402062Grupo Espanol de Tumores Neuroendocrinos17